Lv2
160 积分 2022-09-21 加入
Clinical Immunology
2个月前
已关闭
The hallmarks of oncogenic signaling: from pathways to resistance in cancer therapy
3个月前
已完结
Current Trends in Immuno-Oncology
6个月前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
6个月前
已完结
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
8个月前
已完结
Reducing affinity as a strategy to boost immunomodulatory antibody agonism
8个月前
已完结
皖公网安备34019202002308
